These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 25755102)

  • 1. Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
    Ikeda M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Kondo S; Morizane C; Ueno H; Okusaka T
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):623-7. PubMed ID: 25755102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
    Okuyama H; Ikeda M; Okusaka T; Furukawa M; Ohkawa S; Hosokawa A; Kojima Y; Hara H; Murohisa G; Shioji K; Asagi A; Mizuno N; Kojima M; Yamanaka T; Furuse J
    Neuroendocrinology; 2020; 110(11-12):988-993. PubMed ID: 31986515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
    Morizane C; Machida N; Honma Y; Okusaka T; Boku N; Kato K; Nomura S; Hiraoka N; Sekine S; Taniguchi H; Okano N; Yamaguchi K; Sato T; Ikeda M; Mizuno N; Ozaka M; Kataoka T; Ueno M; Kitagawa Y; Terashima M; Furuse J;
    JAMA Oncol; 2022 Oct; 8(10):1447-1455. PubMed ID: 35980649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
    Yamaguchi T; Machida N; Morizane C; Kasuga A; Takahashi H; Sudo K; Nishina T; Tobimatsu K; Ishido K; Furuse J; Boku N; Okusaka T
    Cancer Sci; 2014 Sep; 105(9):1176-81. PubMed ID: 24975505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
    Zhang P; Li J; Li J; Zhang X; Zhou J; Wang X; Peng Z; Shen L; Lu M
    Cancer; 2020 May; 126 Suppl 9(Suppl 9):2086-2092. PubMed ID: 32293725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
    Fazio N; Spada F; Giovannini M
    Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
    Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
    Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Conversion Surgery after Etoposide/Cisplatin(EP)Therapy for Huge Pancreatic Neuroendocrine Carcinoma - A Case Report].
    Nakazawa A; Mitsui T; Miyata Y; Ninomiya R; Komagome M; Maki A; Ozawa F; Beck Y
    Gan To Kagaku Ryoho; 2018 Mar; 45(3):530-532. PubMed ID: 29650928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
    Nakano K; Takahashi S; Yuasa T; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Tsuyama N; Ishikawa Y; Hatake K
    Jpn J Clin Oncol; 2012 Aug; 42(8):697-703. PubMed ID: 22701038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
    Saijo N; Horiike A
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
    Fujiwara Y; Sekine I; Tsuta K; Ohe Y; Kunitoh H; Yamamoto N; Nokihara H; Yamada K; Tamura T
    Jpn J Clin Oncol; 2007 Jul; 37(7):482-6. PubMed ID: 17652109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
    Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
    Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
    Lamarca A; Frizziero M; Barriuso J; McNamara MG; Hubner RA; Valle JW
    Clin Transl Oncol; 2019 Jul; 21(7):950-953. PubMed ID: 30506132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE; Remotti H; Saif MW; Libutti SK
    JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
    Gupta A; Duque M; Saif MW
    JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
    Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
    World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
    Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
    Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.